Everomus 0.50mg Tablet

About

Everomus 0.50mg Tablet contains Everolimus, an mTOR (mammalian target of rapamycin) inhibitor with immunosuppressive and antiproliferative properties. It is used in a variety of indications, including advanced renal cell carcinoma, advanced pancreatic neuroendocrine tumors, subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis, and hormone receptor-positive, HER2-negative advanced breast cancer. Everolimus works by forming a complex with FKBP-12, which then inhibits mTOR, a central regulator of cell growth, proliferation, and survival.

By blocking the mTOR pathway, Everolimus suppresses tumor cell growth, angiogenesis, and metabolism, making it an effective targeted therapy for several types of cancer. Its immunosuppressive effects also make it useful in preventing organ transplant rejection. The precise dosage and duration of treatment depend on the specific indication and patient response.

Uses

• Treatment of advanced renal cell carcinoma after failure of prior therapy.
• Treatment of advanced pancreatic neuroendocrine tumors.
• Treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis.
• Treatment of hormone receptor-positive, HER2-negative advanced breast cancer in postmenopausal women.

Directions For Use

Take orally once daily, at the same time each day, with or without food, as directed by your physician.

Benefits

• Broad spectrum anti-cancer activity against various solid tumors.
• Inhibits cell growth, proliferation, and angiogenesis through mTOR pathway blockade.
• Oral administration offers convenience for long-term therapy.
• Effective in improving progression-free survival in several advanced cancers.
• Targeted therapy with a distinct mechanism of action.
• Can be used in specific non-oncology indications like tuberous sclerosis.

Side Effects

• Stomatitis (mouth sores)
• Rash
• Fatigue
• Diarrhea
• Nausea
• Anorexia (loss of appetite)
• Peripheral edema
• Hyperglycemia (high blood sugar)
• Hyperlipidemia (high cholesterol)
• Non-infectious pneumonitis
• Infections
• Myelosuppression (low blood counts)

Safety Measures

• Alcohol - Avoid alcohol during treatment as it may worsen side effects like stomatitis, nausea, or potential liver toxicity.
• Pregnancy - Contraindicated in pregnancy due to potential for fetal harm. Women of childbearing potential should use effective contraception.
• Breastfeeding - Not recommended during breastfeeding due to potential harm to the infant. Discontinue breastfeeding during treatment.
• Liver - Dose adjustment is required for patients with hepatic impairment. Use with caution and monitor liver function closely.
• Kidney - No dose adjustment is typically required for mild to moderate renal impairment. Use with caution in severe impairment, though data is limited.
• Lung - Monitor closely for non-infectious pneumonitis, a potentially serious side effect. Report any new or worsening respiratory symptoms immediately.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.